Address: Yildiz Posta Caddesi, Is Bankası Bloklari B Blok Da: 1; 34349 Esentepe / ISTANBUL,Turkey
Tel: +90 (212) 275 96 30
TISD was founded in 1951 in Istanbul, and consist of companies that are all established in Turkey. Currently, TISD has 27 members.
GOALS OF THE ASSOCIATION
• To help Turkish drug manufacturing industry to improve and progress.
• To make professional, technical, and commercial correlations and collaborations (when necessary) among its members, prevent unfair competition, fix conflicts.
• To supply any kind of matters and materials that are dedicated to and needed to be imported on behalf of members of the association, distribute them fairly, and in this regards, represent its members at official departments to contact and conclude issues, prepare necessary printed documents.
• To run the tasks that including drug and drug raw material with its collateral material, manufacturing and improvement of materials, helping to have a license and authorization.
• To accommodate drug prices to have a system that provides industry to improve, adapts to country’s economy, works spontaneously, and is permanent and fair.
• To do all the necessary works at any level for pricing issue
• To participate to decisions
• To be beneficial to its members
Murat Barlas, the longest serving board member for the Turkish Pharmaceutical Manufacturers Association, discusses the need for a new perspective in government-industry relations in the Turkish pharmaceutical industry, and the…
The Turkish minister of labour and social security comments on the country’s deep commitment to providing for the health of citizens while maintaining sustainability and continuous improvement of services. How…
Novo Nordisk Turkey has taken a degree of leadership by working to facilitate and encourage cooperation and collaboration between different stakeholders in the diabetes management ecosystem. For general manager Şebnem…
Turkey is a key market in the region for Servier, says general manager Philippe Méa, largely due to the country’s relatively strong and stable vision for the healthcare industry. The…
Turkey has been a high priority market for Actelion since the company’s relatively recent beginnings, and the general manager of the local affiliate discusses his affiliate efforts to improve awareness…
Bayer Turkey’s healthcare division head discusses how the company adapted to the post 2009 pharmaceutical pricing environment by shrinking their portfolio and focusing strongly on key growth products, launched recently…
Medipol hospital’s medical director discusses the private institution’s current role in the Turkish healthcare system, and their plans for expansion in the coming years. How did Medipol come into existence,…
Professor Burak Erman, the leader of the Drug Research Center at Koç University, and his colleague Hakan Orer, discuss the early activities of the center as a catalyst for collaboration…
Janssen’s MD in Turkey discusses how true innovation is still recognized in Turkey, and how products that meet unmet medical needs are given early access to the country and reimbursement.…
IMS’s top consultant in Turkey discusses the common pattern that companies in Turkey have and must follow to adapt to today’s market, and the importance of heeding market signals, such…
The managing director of Otsuka’s 50-50 joint venture with Turkish giant Abdi Ibrahim, Abdi Ibrahim Otsuka, discusses the mutual advantage the companies can offer each other, and branding Abdi Ibrahim…
Turkey’s Minister of Health discusses the major achievements of his party in the area of healthcare since 2003, and the key priorities for the country’s healthcare system moving forward. During…
See our Cookie Privacy Policy Here
